Glanders: Understanding This Rare Zoonotic Biothreat Pathogen

Glanders is a zoonotic disease caused by Burkholderia mallei, a Gram-negative bacillus that primarily affects equids (horses, donkeys, mules) but can infect humans through occupational exposure. Classified as a Tier 1 select agent due to its aerosol infectivity, low infectious dose, and high mortality if untreated, it represents a significant biothreat concern.

Transmission Pathways

  • Direct contact with infected animal tissues and secretions (nasal, ocular, purulent exudate).
  • Inhalation of infectious aerosols (laboratory, necropsy, slaughter settings).
  • Inoculation through skin abrasions or mucous membranes.
  • No documented human-to-human transmission (rare theoretical cases only).

Clinical Forms in Humans

  • Localized cutaneous (most common): Pustular/nodular lesions at inoculation site ("farcy" if lymphangitic spread); ulcerate and heal with scarring.
  • Pulmonary: Pneumonia, abscesses, pleural effusion; high mortality; may follow inhalation or hematogenous spread.
  • Septicemic: Bacteremia, metastatic abscesses (spleen, liver, muscle), septic shock; fulminant, >90% mortality if untreated.
  • Chronic: Recurrent abscesses, granulomatous lesions persisting months to years.

Equine Disease

  • Nasal form: mucopurulent discharge, septal ulcers, nodules ("glanders nodules").
  • Pulmonary form: pneumonia, nodules.
  • Cutaneous form (farcy): lymphangitis, nodules along lymphatics.
  • Diagnosis: Mallein test (intrapalpebral allergen), PCR, culture.
  • Control: Test and slaughter; no vaccination; strict quarantine.

Human Diagnosis

  • Culture: Definitive; B. mallei grows on standard media (24–48h); oxidase-positive, non-motile, non-lactose fermenter. BSL-3 required.
  • PCR: Real-time assays targeting bimA, tssM; rapid, specific.
  • Serology: Complement fixation, ELISA; cross-reactivity with B. pseudomallei (melioidosis).
  • Imaging: CXR/CT for pulmonary/septicemic forms.

Treatment Regimens

  • Acute/severe: IV meropenem (1g q8h) or imipenem + doxycycline (200 mg q12h) × 10–14 days.
  • Eradication (oral): Doxycycline + TMP-SMX (160/800 mg q12h) × 3–6 months (prevents relapse).
  • Alternatives: Ceftazidime, carbapenems, TMP-SMX monotherapy (mild cases).
  • Post-exposure prophylaxis: Doxycycline 100 mg q12h × 21 days (high-risk exposure).

Infection Control

  • Standard + contact + airborne precautions for pulmonary/septicemic cases.
  • Laboratory: BSL-3; select agent registration (CDC/APHIS).
  • Veterinary reporting mandatory (OIE notifiable).

Glanders is rare but high-consequence. Clinical suspicion in endemic areas or lab workers + rapid BSL-3 confirmation + prompt combination therapy saves lives.

Animal Bites - Related Articles